Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009), a biopharmaceutical company based in China, has announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for its drug candidate AFN0328. The drug is intended for the treatment of malignant tumors associated with HPV16/18 infection, including cervical cancer, anal cancer, vulvar cancer, vaginal cancer, penile cancer, and head and neck cancer. Persistent infection with the human papillomavirus (HPV) can lead to precancerous lesions or cancerous changes in the cervix, anus, vulva, vagina, and other regions. AFN0328, an mRNA drug that targets HPV-associated tumors, is under co-development with Hefei Afana Biotechnology Co., Ltd. Notably, there is currently no similar product available on the global market.- Flcube.com
Recent news:
-
Shanghai Designates Backup Suppliers and Specialized Drug Formulations in GY-YD2024-2 Procurement -
Abbott Laboratories' Volt PFA System Receives EU CE Mark for Atrial Fibrillation Treatment -
Alcon Laboratories Acquires Majority Stake in Aurion Biotech to Advance Eye Disease Cell Therapy -
Genmab's Tivdak Approved in Japan for Advanced Cervical Cancer Treatment -
CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline
